PLMA_1170x120_7-2-21

type 2 diabetes treatment

Jardiance approved to cut cardiovascular death risk

Jardiance approved to cut cardiovascular death risk

RIDGEFIELD, Conn., and INDIANAPOLIS — Jardiance tablets, marketed by Boehringer Ingelheim and Eli Lilly and Co., have been approved by the Food and Drug Administration to cut the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. BI and Lilly said the FDA clearance makes Jardiance (empagliflozin) the first type